GO:1901289 succinyl-CoA catabolic process: Mitochondrial Energy Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901289 succinyl-CoA catabolic process describes the biochemical breakdown of succinyl-CoA, a central mitochondrial acyl-CoA intermediate that feeds the TCA cycle and fuels ATP production.
• The process is executed by succinyl-CoA synthetase (SUCLG1/SUCLA2/SUCLG2) and is coupled to substrate-level phosphorylation, generating succinate and GTP/ATP.
• Succinyl-CoA catabolism is compartmentalized and influences chromatin regulation through succinylation of histones and mitochondrial proteins.
• Dysregulation of succinyl-CoA catabolic flux is linked to chronic heart failure, leukemia progression, liver tumor growth, and antibiotic resistance.
• Key genes include SUCLG1, SUCLA2, SUCLG2, OXCT1, KAT2A, and GTPSCS, which together control succinyl-CoA turnover and downstream succinylation.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of succinyl-CoA catabolic enzymes in disease and metabolism.
Description
GO:1901289 succinyl-CoA catabolic process is defined as the chemical reactions and pathways resulting in the breakdown of succinyl-CoA, a high-energy thioester that occupies a central node in mitochondrial metabolism. Succinyl-CoA is generated by the TCA cycle and by ketone body and amino acid catabolism, and its breakdown is essential for maintaining flux through the TCA cycle and for producing succinate, GTP/ATP, and free CoA. Because succinyl-CoA is a reactive acyl-CoA, its catabolism also controls the availability of succinyl groups for protein succinylation, a post-translational modification that regulates chromatin and mitochondrial function. Researchers study this process to understand how cells balance energy production, biosynthetic demand, and epigenetic signaling, and to identify therapeutic vulnerabilities in cancer and heart failure.
succinyl-CoA catabolic process At A Glance
| GO ID | GO:1901289 |
|---|---|
| GO term | succinyl-CoA catabolic process |
| Ontology | biological_process |
| Synonym | succinyl-CoA breakdown; succinyl-CoA catabolism; succinyl-CoA degradation |
| Major function | Breakdown of succinyl-CoA to succinate and CoA, coupled to GTP/ATP production and regulation of protein succinylation |
| Key enzymes | SUCLG1, SUCLA2, SUCLG2, OXCT1, KAT2A, GTPSCS |
| Subcellular location | Mitochondrial matrix, with nuclear GTPSCS contributing to nuclear succinyl-CoA metabolism |
| Related metabolites | Succinate, CoA, GTP, ATP, acetyl-CoA, ketone bodies |
| Disease relevance | Chronic heart failure, leukemia, liver cancer, antibiotic resistance |
What Is GO:1901289?
In simple terms, GO:1901289 succinyl-CoA catabolic process is the set of enzymatic reactions that break down succinyl-CoA into succinate and CoA, releasing energy that can be captured as GTP or ATP. According to the QuickGO definition, it encompasses the chemical reactions and pathways resulting in the breakdown of succinyl-CoA. This process is primarily mitochondrial and is catalyzed by succinyl-CoA synthetase, which couples succinyl-CoA hydrolysis to substrate-level phosphorylation. The breakdown of succinyl-CoA is not merely a catabolic endpoint; it determines the mitochondrial succinyl-CoA pool that is used for succinylation of histones and other proteins, thereby linking metabolism to gene regulation.
Why Is succinyl-CoA catabolic process Important in Cell Biology?
Succinyl-CoA catabolic process is important because it sits at the intersection of energy metabolism, mitochondrial biogenesis, and epigenetic regulation. The breakdown of succinyl-CoA by succinyl-CoA synthetase is a major source of substrate-level phosphorylation in the TCA cycle, and its dysfunction leads to impaired ATP production and mitochondrial stress in chronic heart failure. In cancer, succinyl-CoA catabolism supports leukemia progression by restricting POLRMT succinylation and enhancing mitochondrial biogenesis, and it promotes ketolysis and liver tumor growth through OXCT1 succinylation. Moreover, the succinyl-CoA pool directly influences histone succinylation and gene expression, connecting this catabolic process to chromatin regulation and cell fate decisions. Understanding GO:1901289 is therefore essential for researchers in metabolism, epigenetics, and oncology.
• Provides a key step in the TCA cycle by converting succinyl-CoA to succinate, supporting mitochondrial energy production.
• Generates GTP/ATP through substrate-level phosphorylation, contributing to cellular energy homeostasis.
• Controls the mitochondrial and nuclear pools of succinyl-CoA available for protein succinylation.
• Regulates histone succinylation and chromatin state, linking metabolism to gene expression.
• Dysfunction is associated with chronic heart failure and impaired mitochondrial energy metabolism.
• Supports leukemia progression by modulating POLRMT succinylation and mitochondrial biogenesis.
• Promotes ketolysis and liver tumor growth via OXCT1 succinylation and activation.
• Influences antibiotic resistance through metabolism-dependent succinylation and resource allocation.
• Is a target for therapeutic intervention in metabolic diseases and cancer.
• Can be studied with CRISPR models to dissect causal roles of SUCLG1, SUCLA2, and OXCT1.
What Happens During succinyl-CoA catabolic process?
Substrate-level phosphorylation by succinyl-CoA synthetase
In simple terms: The enzyme succinyl-CoA synthetase breaks down succinyl-CoA and uses the released energy to make GTP or ATP.
The central reaction of GO:1901289 is catalyzed by succinyl-CoA synthetase, a heterodimeric enzyme composed of a catalytic subunit (SUCLA2 or SUCLG2) and a shared alpha subunit (SUCLG1). This enzyme converts succinyl-CoA and GDP/ADP and inorganic phosphate into succinate, CoA, and GTP/ATP. The reaction is reversible but under physiological conditions contributes to succinyl-CoA catabolism and substrate-level phosphorylation in the TCA cycle. Structural and biochemical studies have shown that the enzyme can be inhibited by tartryl-CoA, a non-hydrolyzable analog, providing insight into its catalytic mechanism.
Coupling to the TCA cycle and ketone body metabolism
In simple terms: Succinyl-CoA breakdown is linked to the TCA cycle and to the use of ketone bodies for energy.
Succinyl-CoA is an intermediate of the TCA cycle, and its catabolism is tightly coupled to the overall flux of the cycle. In ketolytic tissues, succinyl-CoA is also generated from ketone bodies via OXCT1, and its subsequent breakdown by succinyl-CoA synthetase is required for ketolysis and energy production. OXCT1 activity is regulated by succinylation, and SUCLA2 promotes OXCT1 succinylation and activation, linking succinyl-CoA catabolism to ketone body utilization and liver tumor growth.
Compartmentalization and nuclear functions
In simple terms: Succinyl-CoA breakdown happens mainly in mitochondria, but related enzymes also act in the nucleus.
Succinyl-CoA metabolism is compartmentalized, with the mitochondrial matrix being the primary site of succinyl-CoA catabolism. However, nuclear GTPSCS has been shown to function as a lactyl-CoA synthetase and to promote histone lactylation and gliomagenesis, indicating that acyl-CoA metabolism extends beyond mitochondria. The compartmentalization of acyl-CoA metabolism influences chromatin regulation, as different pools of succinyl-CoA can be used for histone succinylation.
Regulation by succinylation and feedback
In simple terms: The breakdown of succinyl-CoA is controlled by chemical modifications of the enzymes themselves.
Succinyl-CoA catabolic enzymes are subject to regulation by succinylation. For example, SUCLG1 restricts POLRMT succinylation to enhance mitochondrial biogenesis and leukemia progression, demonstrating that succinyl-CoA catabolism can influence mitochondrial gene expression through post-translational modifications. Similarly, OXCT1 succinylation and activation by SUCLA2 promotes ketolysis and liver tumor growth, showing that succinylation of metabolic enzymes is a key regulatory layer. Metabolism-dependent succinylation also governs resource allocation for antibiotic resistance, highlighting the broad impact of succinyl-CoA catabolism on cellular physiology.
Key Genes Involved in GO:1901289 succinyl-CoA catabolic process
The following genes encode enzymes and regulatory proteins that directly participate in or regulate succinyl-CoA catabolic process (GO:1901289).
| Gene | Major Role | Research Relevance |
|---|---|---|
| SUCLG1 | Alpha subunit of succinyl-CoA synthetase; essential for succinyl-CoA catabolism | Restricts POLRMT succinylation; linked to leukemia progression |
| SUCLA2 | Catalytic subunit of succinyl-CoA synthetase (GTP-forming) | Promotes OXCT1 succinylation and ketolysis in liver tumor growth |
| SUCLG2 | Catalytic subunit of succinyl-CoA synthetase (ATP-forming) | Contributes to succinyl-CoA catabolism in various tissues |
| OXCT1 | Ketone body utilization; generates succinyl-CoA for catabolism | Succinylation and activation by SUCLA2 promotes liver tumor growth |
| KAT2A | Histone H3 succinyltransferase coupled to alpha-KGDH complex | Links succinyl-CoA metabolism to chromatin regulation |
| GTPSCS | Nuclear succinyl-CoA synthetase; lactyl-CoA synthetase activity | Promotes histone lactylation and gliomagenesis |
| POLRMT | Mitochondrial RNA polymerase; regulated by succinylation | Succinylation by succinyl-CoA affects mitochondrial biogenesis |
| Alpha-KGDH complex | Generates succinyl-CoA from alpha-ketoglutarate | Provides substrate for succinyl-CoA catabolism and histone succinylation |
| SUCLA2/SUCLG2 heterodimers | Catalytic core of succinyl-CoA synthetase | Targets for structural and inhibitor studies |
| Tartryl-CoA (metabolite) | Inhibitor of succinyl-CoA synthetase | Used to probe enzyme mechanism |
| Succinate | Product of succinyl-CoA catabolism | Signals metabolic state and affects chromatin |
| CoA | Product of succinyl-CoA catabolism | Essential for acyl-CoA metabolism |
| GTP/ATP | Energy carriers produced by substrate-level phosphorylation | Reflects energy status of the cell |
| SIRT5 (contextual) | Desuccinylase that removes succinyl groups | Modulates succinylation landscape |
| CPT1A (contextual) | Fatty acid oxidation enzyme; affected by succinylation | Links succinyl-CoA metabolism to lipid metabolism |
| ACAT1 (contextual) | Ketone body metabolism; related to OXCT1 | Contributes to succinyl-CoA pool |
How Is succinyl-CoA catabolic process Regulated?
Succinyl-CoA catabolic process is regulated at multiple levels. The expression and activity of succinyl-CoA synthetase subunits (SUCLG1, SUCLA2, SUCLG2) determine the capacity for succinyl-CoA breakdown. Post-translational succinylation of enzymes such as OXCT1 and POLRMT modulates their activity and downstream pathways. The availability of substrates (succinyl-CoA, GDP/ADP, phosphate) and products (succinate, CoA, GTP/ATP) provides feedback regulation. Additionally, compartmentalization of acyl-CoA pools between mitochondria and nucleus influences chromatin succinylation and gene expression. Metabolism-dependent succinylation further integrates succinyl-CoA catabolism with cellular resource allocation and stress responses.
succinyl-CoA catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SUCLG1 | Leukemia progression | Knockout and overexpression in leukemia cell lines |
| SUCLA2 | Liver tumor growth | Knockout and point-mutation models in hepatoma cells |
| OXCT1 | Liver tumor growth and ketolysis | Knock-in of succinylation-resistant mutants |
| GTPSCS | Gliomagenesis | Knockout and overexpression in glioma models |
| KAT2A | Chromatin regulation and cancer | Knockout and catalytic-dead point mutants |
Chronic heart failure
Succinyl-CoA-based energy metabolism dysfunction has been observed in chronic heart failure, where impaired succinyl-CoA catabolism contributes to reduced ATP production and mitochondrial dysfunction. This suggests that targeting succinyl-CoA catabolic enzymes could improve cardiac energy metabolism.
Leukemia progression
SUCLG1 restricts POLRMT succinylation to enhance mitochondrial biogenesis and leukemia progression, indicating that succinyl-CoA catabolism supports leukemic cell growth. Inhibition of this pathway may represent a therapeutic strategy for leukemia.
Liver tumor growth
OXCT1 succinylation and activation by SUCLA2 promotes ketolysis and liver tumor growth, linking succinyl-CoA catabolism to cancer metabolism. Targeting OXCT1 or SUCLA2 may disrupt tumor energy supply.
Antibiotic resistance
Metabolism-dependent succinylation governs resource allocation for antibiotic resistance, suggesting that succinyl-CoA catabolism influences bacterial stress responses and resistance mechanisms.
From succinyl-CoA catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SUCLG1 affect succinyl-CoA catabolism and leukemia progression? | SUCLG1 knockout cell lines |
| Does SUCLA2-mediated OXCT1 succinylation promote liver tumor growth? | SUCLA2 knockout and OXCT1 succinylation-site point mutants |
| Does nuclear GTPSCS contribute to histone lactylation and gliomagenesis? | GTPSCS knockout and knock-in of catalytic mutants |
| How does KAT2A-mediated histone succinylation respond to succinyl-CoA levels? | KAT2A knockout and overexpression models |
| Can tartryl-CoA inhibit succinyl-CoA synthetase in cells? | Point mutations in SUCLA2/SUCLG2 active site |
| Does metabolism-dependent succinylation affect antibiotic resistance? | Knockout of succinyl-CoA catabolic genes in bacteria |
How to Study the succinyl-CoA catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Levels of succinyl-CoA, succinate, CoA, GTP/ATP | Assessing catabolic flux in cells and tissues |
| 13C isotope tracing | Flux through succinyl-CoA catabolic pathway | Determining pathway activity and compartmentalization |
| Succinylome proteomics | Protein succinylation sites and abundance | Linking succinyl-CoA catabolism to chromatin and mitochondrial regulation |
| CRISPR knockout screens | Genes required for succinyl-CoA catabolism | Identifying therapeutic targets in cancer |
| Enzyme activity assays | Succinyl-CoA synthetase activity | Testing inhibitors and mutants |
| Crystallography | Three-dimensional structure of enzyme-inhibitor complexes | Understanding catalytic mechanism |
| Western blot with anti-succinyllysine | Global succinylation levels | Validating changes in succinylation |
| Seahorse respirometry | Mitochondrial respiration and ATP production | Assessing energy metabolism in knockout cells |
Metabolomics and flux analysis
Mass spectrometry-based metabolomics can quantify succinyl-CoA, succinate, CoA, and related metabolites to assess succinyl-CoA catabolic flux. Isotope tracing with 13C-labeled substrates can determine pathway activity and compartmentalization.
Proteomics and succinylome analysis
Succinylation-specific proteomics using anti-succinyllysine antibodies can identify proteins modified by succinyl-CoA, including histones and mitochondrial proteins. This approach reveals how succinyl-CoA catabolism influences the succinylome.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens can identify genes required for succinyl-CoA catabolism and its downstream effects on cell growth and survival. Focused screens targeting metabolic enzymes can uncover synthetic lethal interactions.
Structural and biochemical assays
Recombinant succinyl-CoA synthetase can be used for enzymatic assays and crystallography to study catalytic mechanism and inhibition by tartryl-CoA. These assays measure substrate-level phosphorylation and enzyme kinetics.
How CRISPR Can Be Used to Study GO:1901289 succinyl-CoA catabolic process
Knockout
CRISPR knockout of SUCLG1, SUCLA2, SUCLG2, OXCT1, or GTPSCS can abolish succinyl-CoA catabolic flux, leading to accumulation of succinyl-CoA and reduced succinate production. These models are used to study the consequences of pathway loss on mitochondrial function, cell growth, and disease progression.
Point Mutation
Point mutations in catalytic residues of succinyl-CoA synthetase or in succinylation sites of OXCT1 and POLRMT can dissect the specific contributions of enzymatic activity versus post-translational modification. For example, succinylation-resistant mutants of OXCT1 can test whether succinylation is required for ketolysis and tumor growth.
Knock-in
Knock-in of tagged or mutant versions of SUCLG1, SUCLA2, or GTPSCS allows tracking of protein localization and function in vivo. Tagged knock-in models can be used for affinity purification and interactome studies.
Overexpression
Overexpression of wild-type or mutant succinyl-CoA catabolic enzymes can enhance pathway flux and succinylation, providing gain-of-function models to study disease mechanisms such as leukemia and liver cancer. Overexpression of KAT2A can increase histone succinylation and alter chromatin state.
How EDITGENE Supports succinyl-CoA catabolic process Research
Researchers studying succinyl-CoA catabolic process-related genes often need to determine whether a candidate gene is causally involved in metabolic regulation, disease progression, or therapeutic response. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models that enable such causal studies.
Contact EDITGENE today to design your custom CRISPR model for succinyl-CoA catabolic process research.
Frequently Asked Questions About succinyl-CoA catabolic process
What is succinyl-CoA catabolic process?
Succinyl-CoA catabolic process (GO:1901289) is the set of biochemical reactions that break down succinyl-CoA into succinate and CoA, often coupled to GTP or ATP production.
What genes are involved in succinyl-CoA catabolic process?
Key genes include SUCLG1, SUCLA2, SUCLG2, OXCT1, GTPSCS, and KAT2A, which encode enzymes and regulatory proteins that control succinyl-CoA turnover and succinylation.
Where does succinyl-CoA catabolic process occur in the cell?
It occurs primarily in the mitochondrial matrix, although nuclear GTPSCS also contributes to acyl-CoA metabolism and histone modification.
What is the role of succinyl-CoA synthetase in succinyl-CoA catabolism?
Succinyl-CoA synthetase catalyzes the conversion of succinyl-CoA to succinate, producing GTP or ATP through substrate-level phosphorylation.
How is succinyl-CoA catabolic process linked to cancer?
It supports leukemia progression by regulating POLRMT succinylation and mitochondrial biogenesis, and promotes liver tumor growth through OXCT1 succinylation and ketolysis.
What diseases are associated with defects in succinyl-CoA catabolism?
Chronic heart failure, leukemia, liver cancer, and antibiotic resistance have been linked to altered succinyl-CoA catabolic flux.
How can CRISPR be used to study succinyl-CoA catabolic process?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to dissect the causal roles of specific genes in succinyl-CoA catabolism and disease.
What methods are used to measure succinyl-CoA catabolic flux?
LC-MS metabolomics, 13C isotope tracing, succinylome proteomics, and enzyme activity assays are commonly used to measure pathway activity.
Is succinyl-CoA catabolism related to histone modification?
Yes, succinyl-CoA is a substrate for histone succinylation, and enzymes like KAT2A and GTPSCS link succinyl-CoA metabolism to chromatin regulation.
What is the clinical relevance of succinyl-CoA catabolic process?
It is a potential therapeutic target in heart failure and cancer, and its dysfunction contributes to metabolic and mitochondrial diseases.
Conclusion
GO:1901289 succinyl-CoA catabolic process is a fundamental mitochondrial pathway that controls energy production, protein succinylation, and cellular metabolism. Its dysregulation is implicated in chronic heart failure, leukemia, liver cancer, and antibiotic resistance, making it a compelling target for therapeutic intervention. By combining CRISPR-based genetic models with metabolomics and proteomics, researchers can dissect the precise roles of SUCLG1, SUCLA2, OXCT1, and other key genes in health and disease.
References
- 1. Liu R et al.. 2025. Nuclear GTPSCS functions as a lactyl-CoA synthetase to promote histone lactylation and gliomagenesis.. Cell Metab 37(2):377-394.e9 PMID: 39642882
- 2. Wang Y et al.. 2017. KAT2A coupled with the α-KGDH complex acts as a histone H3 succinyltransferase.. Nature 552(7684):273-277 PMID: 29211711
- 3. Trefely S et al.. 2020. Compartmentalised acyl-CoA metabolism and roles in chromatin regulation.. Mol Metab 38:100941 PMID: 32199817
- 4. Takada S et al.. 2022. Succinyl-CoA-based energy metabolism dysfunction in chronic heart failure.. Proc Natl Acad Sci U S A 119(41):e2203628119 PMID: 36201541
- 5. Yan W et al.. 2024. SUCLG1 restricts POLRMT succinylation to enhance mitochondrial biogenesis and leukemia progression.. EMBO J 43(12):2337-2367 PMID: 38649537
- 6. Guo D et al.. 2025. OXCT1 succinylation and activation by SUCLA2 promotes ketolysis and liver tumor growth.. Mol Cell 85(4):843-856.e6 PMID: 39862868
- 7. Huang J et al.. 2020. Tartryl-CoA inhibits succinyl-CoA synthetase.. Acta Crystallogr F Struct Biol Commun 76(Pt 7):302-308 PMID: 32627745
- 8. Wu JH et al.. 2025. Metabolism-dependent succinylation governs resource allocation for antibiotic resistance.. Sci Adv 11(34):eadu2856 PMID: 40845110
